RESULTS:
For the RNA-SNP approach, we achieved a diagnostic sensitivity and specificity of 100% (95% CI, 40.2%-100%) and 89.7% (95% CI, 78.8%-96.1%), respectively, for both the MS and the digital PCR methods. For the mRNA-quantification approach, the areas under the ROC curves were 0.859 (95% CI, 0.741-0.903) and 0.833 (95% CI, 0.770 -0.923) for plasma PLAC4 mRNA concentrations measured by the real-time PCR and the digital PCR methods, respectively.
CONCLUSIONS:
For prenatal screening of trisomy 21, the quantification of the total PLAC4 mRNA concentration can be used in a synergistic manner with the RNA-SNP allelic ratio approach to increase the population coverage of cases in which diagnostic information can be obtained.
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Current definitive methods for prenatal diagnosis of chromosomal aneuploidy include amniocentesis and chorionic villus sampling, which are invasive and associated with a finite risk of fetal loss (1) (2) (3) . Noninvasive screening methods with sonographic and maternal serum biochemical markers have been developed (4 -6 ) , but these markers do not target the core chromosomal abnormality and have suboptimal diagnostic accuracies.
Since 1997, circulating fetal nucleic acids in the maternal plasma have offered new possibilities for noninvasive prenatal diagnosis (7) (8) (9) . Recently, several important developments have been made for the use of cell-free fetal nucleic acids to identify fetal aneuploidies (10 -14 ) . One such method is to measure the ratio of alleles for a single-nucleotide polymorphism (SNP) 5 in placenta-derived mRNA molecules in maternal plasma, which is termed the "RNA-SNP approach" (11 ) . PLAC4 (placenta-specific 4) mRNA (15 ) , which is transcribed from chromosome 21 in the placenta and is specific for the fetus in maternal plasma, has been used for this approach (11 ) . Such RNA-SNP analysis is applicable to pregnant women with a fetus heterozygous for the studied SNP in the PLAC4 gene. Studies with a mass spectrometry (MS)-based method for measuring the allelic ratio (16 ) have found that pregnant women who carry trisomy 21 fetuses have PLAC4 RNA-SNP allelic ratios in the maternal plasma that deviate from those in women carrying euploid fetuses.
The method has a reported diagnostic sensitivity of 90% and a specificity of 96.5% for identifying trisomy 21 fetuses with just a single marker, a performance comparable to that of many multimarker screening strategies (6 ) .
One critical factor affecting the accuracy of the RNA-SNP approach is that samples of maternal plasma should contain sufficient mRNA molecules so that MS can reliably detect the allelic ratio (11 ) . To enhance the precision, investigators have used a platform based on the digital PCR in the RNA-SNP approach, which has been termed the "digital RNA-SNP" approach (12 ) . This method uses the digital PCR (17 ) to directly count the number of each of the alleles present in the plasma sample (18, 19 ) . The method has been demonstrated to accurately classify informative euploid and trisomy 21 fetuses noninvasively with maternal plasma (12 ) .
Besides the RNA-SNP approach, the fetal chromosome 21 dosage can potentially be assessed by measuring the total concentration of PLAC4 mRNA in maternal plasma. It has previously been suggested that the plasma concentration of a chromosome 21-transcribed placental mRNA would be increased in trisomy 21 pregnancies because of the transcription of the extra gene copy in the placenta (20 ) . In fact, a trend toward an increased PLAC4 mRNA concentration in the maternal plasma of trisomy 21 pregnancies has already been reported, but the increase did not reach statistical significance (11 ) .
In this study, we investigated the feasibility of integrating the RNA-SNP approach and the circulating mRNA-quantification approach for detecting trisomy 21 fetuses with PLAC4 mRNA molecules in maternal plasma. We introduced the mRNA-quantification approach because the method could potentially be used for screening pregnancies involving homozygous fetuses, for which the RNA-SNP approach cannot be applied.
Materials and Methods

GENERAL STRATEGY
The strategy used in this study is outlined in Fig. 1 . We first determined the fetal PLAC4 SNP genotype from a sample of maternal plasma. We then analyzed heterozygous and homozygous cases by the PLAC4 RNA-SNP approach and the PLAC4 mRNA-quantification approach, respectively. For each of the approaches, the diagnostic sensitivities and specificities for the "conventional" (i.e., nondigital) and "digital" methods were compared. For the RNA-SNP approach, this comparison was between the MS-based and the digital PCR-based measurements of the RNA-SNP allelic ratio. For the measurement of total PLAC4 mRNA concentration, the comparison was between real-time PCR and digital PCR quantification.
STUDY PARTICIPANTS
We recruited, with informed consent, a consecutive series of pregnant women at the King's College Hospital London, London, UK. Pregnant women attending their first routine visits in the hospital were offered screening for chromosomal abnormalities, which involved measurement of nuchal translucency and measurement of free ␤ human chorionic gonadotropin and pregnancy-associated plasma protein A in maternal serum. For the identified high-risk women, chorionic villus sampling was offered. The women who chose to undergo the procedure were invited to participate in the study. Only women with singleton pregnancies were recruited. We collected 10 mL of maternal peripheral blood into EDTA-containing tubes immediately before the procedure. Karyotyping was performed to ascertain the fetal chromosomal status. Ethics approval for the clinical research was granted by the King's College Hospital Ethics Committee.
SAMPLE PROCESSING
We stored the unprocessed blood samples at 4°C upon collection and harvested plasma from the blood samples within 6 h (21 ). The blood samples were centrifuged at 1600 g for 10 min at 4°C. The plasma portion was transferred into clean polypropylene tubes and recentrifuged at 16 000 g for 10 min at 4°C. We added 1.2 mL of TRIzol LS reagent (Invitrogen) per 0.4 mL of plasma before storage at Ϫ80°C. Finally, the plasma samples were shipped on dry ice to the Prince of Wales Hospital, Hong Kong, for molecular analysis.
All experimental procedures were carried out by a research assistant who had no knowledge of the fetal karyotypes. We extracted RNA from 3.2 mL of plasma. For every 1.6 mL of the plasma-TRIzol LS mixture prepared as described above, 320 L of chloroform was added. After vortex-mixing and subsequent centrifugation at 12 000g for 15 min at 4°C, the aqueous phase was transferred to a new tube, and 457 L of 100% ethanol was added. All of the mixture from a single sample was applied to an RNeasy Mini Spin Column (Qiagen) with further processing according to the manufacturer's protocol. We eluted the RNA with 48 L of RNase-free water. The extracted plasma RNA was then treated with DNase I (Invitrogen) according to the manufacturer's protocol to remove contaminating genomic DNA. The protocol has previously been shown to efficiently remove contaminating genomic DNA.
We then reverse-transcribed 62.4 L of the DNase I-treated RNA with a gene-specific reversetranscription primer and ThermoScript reverse tran-scriptase (Invitrogen) according to the manufacturer's recommendations. The sequence of the reversetranscription primer is 5Ј-AGTATATAGAACCATG TTTAGGCCAGA-3Ј (Integrated DNA Technologies). A final cDNA volume of approximately 104 L was obtained.
REAL-TIME QUANTITATIVE PCR
We quantified the cDNA samples by a real-time PCR assay directed toward PLAC4 mRNA (NM_182832.2) with the primers 5Ј-CCGCTAGGGTGTCTTTTAA GC-3Ј and 5Ј-GTGTTGCAATACAAAATGAGTT TCT-3Ј, and the fluorescent probe 5Ј-(FAM)ATT GGAGCAAATTC(MGBNFQ)-3Ј (Applied Biosystems), where FAM is 6-carboxyfluorescein and MGBNFQ is a minor groove-binding nonfluorescent quencher. The assay produced an 80-bp amplicon. A calibration curve was prepared by serially diluting an HPLC-purified single-stranded synthetic DNA oligonucleotide (Proligos) specifying the amplicon. The sequence was 5Ј-CGCCGCTAGGGTGTCTTTTAAG CTATTGGAGCAAATTCAAATTTGGCTTAAAGAA AAAGAAACTCATTTTGTATTGCAACACCAGGAG TATCCCAAGGGACTCG-3Ј. Each cDNA sample was analyzed in duplicate. Five microliters of cDNA were used for each reaction. The reaction was set up with 2ϫ Maternal plasma samples were analyzed for each of the 2 approaches by both the "conventional" and the "digital" methods.
TaqMan Universal PCR Master Mix (Applied Biosystems) in a reaction volume of 25 L. The amounts of each of the primers and the probe used in each reaction were 400 nmol/L and 160 nmol/L, respectively. The reaction was carried out in an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). It was initiated at 50°C for 2 min and continued at 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 57°C for 1 min. The fluorescence signals were collected and analyzed with SDS 2.1 software (Applied Biosystems). Details of the real-time PCR experiments are described in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol56/issue1.
DIGITAL PCR
We performed the digital PCR in 384-well plates with a set of primers that specify the rs8130833 SNP in the PLAC4 gene (11, 12 ) . The primers used were 5Ј-TTTGTATTGCAACACCATTTGG-3Ј and the genespecific reverse-transcription primer described above. Two allele-specific fluorescent probes targeting each of the 2 alleles were designed. Their sequences are 5Ј-(FAM)TCGTCgTCTAACTTG(MGBNFQ)-3Ј and 5Ј-(VIC)ATTCGTCaTCTAACTTG(MGBNFQ)-3Ј for the G and A alleles, respectively. The letters in lowercase denote the polymorphic nucleotides distinguishing the SNP alleles. For each digital PCR, the input cDNA volume was estimated from the real-time PCR data so that approximately 1 template molecule was added per well (12, 22 ) . cDNA (maximum volume, 45 L) was added to the reaction. A 384-well digital reaction was performed for each sample. The reaction was set up and performed in a reaction volume of 5 L/ well, as previously described (12 ) . The number of wells that were positive for either the A or G allele was computed automatically by the SDS 2.2.2 software (Applied Biosystems).
To genotype the PLAC4 SNP, we counted the number of wells positive for either the A or the G allele. To calculate the RNA-SNP allelic ratio, we divided the Poisson-corrected counts for the G-allele copies by the Poisson-corrected counts for the A-allele according to the following equation: 
MS RNA-SNP ANALYSIS
PLAC4 cDNA (45 L) was PCR-amplified in a total reaction volume of 90 L with the primers 5Ј-ACGTT GGATGGTATTGCAACACCATTTGGG-3Ј and 5Ј-AC GTTGGATGTAGAACCATGTTTAGGCCAG-3Ј. The SNP allelic ratios were then determined by a homogeneous MassEXTEND assay (Sequenom) with extension primer 5Ј-AGGCCAGATATATTCGTC-3Ј. The PCR and homogeneous MassEXTEND reactions were set up and performed as described previously (11 ) . The baseextension products were analyzed by a MassARRAY Analyzer Compact mass spectrometer (Sequenom), and the relative abundances of the 2 SNP alleles were calculated automatically by the SpectroTYPER software (Sequenom). The allelic ratios for the heterozygous samples were calculated by dividing the relative amount of the G allele by the relative amount of the A allele.
To evaluate the reproducibility of the RNA-SNP allelic ratio measurements, we prepared cDNAs from 2 euploid and 2 trisomy 21 placentas and quantified them by the real-time PCR. The cDNA samples were then diluted to approximately 1446 copies of PLAC4 cDNA per PCR, a concentration that mimics the mean PLAC4 cDNA concentration in first-trimester maternal plasma.
STATISTICAL ANALYSIS
We used the nonparametric Mann-Whitney test and the parametric Student t-test to detect statistically significant differences between groups. The correlation of data obtained by different detection methods was tested by means of the Pearson product moment correlation. ROC curve analysis was used to estimate diagnostic sensitivities and specificities, as well as the areas under ROC curves. Statistical analyses were performed with SigmaStat 3.5 (Systat Software) and MedCalc 9.6.0 (MedCalc Software). A difference with P value Ͻ0.05 was considered statistically significant.
Results
STUDY PARTICIPANTS
We prospectively recruited 168 individuals between August and October 2008. Euploid and trisomy 21 fetuses were confirmed in 137 women and 16 women, respectively. Fifteen women carrying aneuploid fetuses other than trisomy 21 (6 with trisomy 18, 2 with trisomy 13, 3 with Turner syndrome, 2 with triploid, and 1 with 47XXY) and 1 woman without karyotyping data were excluded from the study. The mean (SD) gestational ages for the euploid and trisomy 21 groups were 12.8 (0.7) weeks and 12.9 (0.5) weeks, respectively. The mean maternal age was 34.8 (6.1) years for the euploid group and 34.8 (6.3) years for the trisomy 21 group. No significant differences between the euploid and the trisomy 21 groups were found with respect to either gestational age or maternal age (Mann-Whitney rank sum test: P ϭ 0.823 for the gestational-age comparison, P ϭ 0.979 for the maternal-age comparison). For the euploid cases, 79.6% of the women were Caucasian, 13.9% were Afro-Caribbean, and 6.6% were of other ethnicities. For the trisomy 21 cases, 87.5% and 12.5% were Caucasian and Afro-Caribbean, respectively.
PLAC4 SNP GENOTYPING
The fetal origin of PLAC4 mRNA in maternal plasma allowed us to genotype the PLAC4 SNP of the fetuses from maternal plasma. For the MS-based genotyping, samples that showed the specific base-extension product peak for either the A or G allele were classified as homozygous, and samples that showed product peaks for both alleles were classified as heterozygous. For the digital PCR genotyping, 91 samples showed either A-positive or G-positive wells constituting 98%-100% of the total positive wells in the 384-well reaction. These samples were classified as homozygous. The remaining 62 samples in which either the A-positive wells or the G-positive wells constituted 50%-72% of the total positive wells were classified as heterozygous.
The genotyping results produced by the MS and digital PCR methods were identical. Sixty-two and 91 pregnancies carried fetuses that were heterozygous and homozygous, respectively, for the PLAC4 SNP.
RNA-SNP ANALYSIS OF HETEROZYGOUS CASES
We measured PLAC4 RNA-SNP allelic ratios in 58 euploid and 4 trisomy 21 heterozygous cases by the MS and digital PCR methods ( Table 1 ). The allelic ratios determined with the 2 methods were significantly correlated (r ϭ 0.926, Pearson correlation; P Ͻ 0.001). We observed that the allelic ratio values obtained with the digital PCR method were closer to the expected values (i.e., 2 or 0.5 for a trisomy 21 fetus and 1 for a euploid fetus) than the ratios obtained by the MS method. We reasoned that the digital PCR method directly counted the numbers of A and G alleles present in the samples. Such absolute quantification was less likely to be influenced by analytical parameters and thus would more accurately reflect the true values. On the other hand, the allelic ratios obtained by the MS method were smaller than the expected values because of the inherent property of MS to have a reduced peak intensity for the higher-mass product (23 ) .
Because the allelic ratios for both the MS and the digital PCR measurements did not follow a normal distribution (P Ͻ 0.001 for both methods, KolmogorovSmirnov test), we defined the upper and lower cutoffs as the 95th and 5th percentiles of the allelic ratios of the euploid group. Samples with allelic ratios falling within the 2 cutoffs were classified as euploid, and samples falling outside the cutoffs were classified as trisomy 21. With these cutoffs, we achieved a sensitivity and specificity of 100% (95% CI, 40.2-100%) and 89.7% (95% CI, 78.8 -96.1%), respectively, for both the MS and the digital methods (Fig. 2) . We evaluated the reproducibility of MS measurement of the allelic ratio. The within-run CVs for 20 repeated allelic ratio measurements in 2 euploid and 2 trisomy 21 cases ranged from 6.5% to 12%. The between-day CVs were determined by measuring the allelic ratios in the 2 euploid and 2 trisomy 21 cases once per day for 5 days; these CVs ranged from 8.4% to 14%.
ANALYSIS OF PLAC4 mRNA CONCENTRATION FOR HOMOZYGOUS
CASES
We measured total PLAC4 cDNA concentration in 79 euploid and 12 trisomy 21 homozygous plasma samples by real-time PCR and digital PCR ( Table 1) . The concentrations measured with the 2 methods were significantly correlated (r ϭ 0.972, Pearson correlation; P Ͻ 0.001). We observed no systematic bias between the 2 methods (see Fig. 1 in the online Data Supplement). For most of the analyzed samples, the concentrations measured by the real-time PCR were higher than those measured with the digital PCR method by a mean of 1.75-fold. We reasoned that whereas the digital PCR measured the actual PLAC4 cDNA concentration in the samples, the real-time PCR measured the PLAC4 cDNA abundance with reference to the calibration curve of the oligonucleotide calibrator, which was estimated from spectrometric data provided by the manufacturer and thus might have deviated from the actual concentration.
We detected significant increases in the plasma PLAC4 cDNA concentration in the trisomy 21 pregnancies with both quantification methods (P Ͻ 0.001 for both methods, Mann-Whitney rank sum test). The areas under the ROC curves were 0.859 (95% CI, 0.770 -0.923) for the real-time PCR quantification and 0.833 (95% CI, 0.741-0.903) for the digital PCR quantification (Fig. 3) . We observed no significant difference between the ROC curves obtained with the 2 quantification methods (P ϭ 0.574, pairwise comparison). We further determined from the ROC curves the cutoff concentration values that gave the optimal diagnostic sensitivities and specificities. For the real-time PCR method, a sensitivity of 91.7% (95% CI, 61.5%-98.6%) and a specificity of 81.0% (95% CI, 70.6%-89.0%) were obtained at a cutoff of 1106 copies/mL (Fig. 4A) . The cutoff value for the digital PCR method The solid line and the dashed line represent real-time PCR and digital PCR quantifications, respectively.
was 695 copies/mL, which yielded a sensitivity of 83.3% (95% CI, 51.6%-97.4%) and a specificity of 83.5% (95% CI, 73.5%-90.9%) (Fig. 4B) . At a fixed falsepositive rate of 10%, the detection sensitivities were 16.7% (95% CI, 2.5%-48.4%) and 33.3% (95% CI, 10.1%-65.1%) for the real-time PCR and the digital PCR methods, respectively. Because the PLAC4 mRNA concentration data for maternal plasma were also available for the heterozygous samples, we combined the data of both the homozygous and heterozygous cases and repeated the analysis (see Table 1 and Fig. 2 in the online Data Supplement). The ROC curves obtained for only the homozygous samples and for the group of combined samples were not significantly different (2-tailed comparisons: P ϭ 0.540 for the real-time PCR analysis; P ϭ 0.715 for the digital PCR analysis).
Discussion
In this study, we have outlined and demonstrated a combined strategy for using fetal-derived PLAC4 mRNA in maternal plasma to screen for trisomy 21 fetuses noninvasively. The strategy involves the synergistic use of the measurement of the total PLAC4 mRNA concentration and the RNA-SNP allelic ratio. Both methods basically target the core genetic abnormalities of trisomy 21. The RNA-SNP approach detects the deviated RNA-SNP allelic ratio on PLAC4 mRNA caused by the imbalance in chromosome 21 dosage. The circulating mRNA-quantification approach detects the increased PLAC4 mRNA concentration, which might be a consequence of a gene-dosage effect due to the presence of an extra chromosome 21. Further studies, however, are required to investigate whether other factors, such as increased apoptosis in aneuploid placentas (24 ) , contribute to the increase.
We used plasma samples from pregnancies in which the fetus was heterozygous for the PLAC4 SNP to compare the diagnostic accuracies of the RNA-SNP approach on the MS (11 ) and digital PCR (12 ) platforms. We demonstrated that the 2 methods for measuring the allelic ratio had identical diagnostic sensitivities and specificities of 100% and 89.7%, respectively (Table 2) . This result supports the value of the RNA-SNP approach for the clinical detection of trisomy 21 fetuses. In the current study, we used nonparametric statistics to derive a diagnostic cutoff because the current data sets for the allelic ratio were not normally distributed. We have shown that the concentration of PLAC4 mRNA in maternal plasma is useful for screening trisomy 21 fetuses that are homozygous for the targeted PLAC4 SNP. The diagnostic accuracies of the real-time PCR and the digital PCR quantification methods were similar, as is shown by the absence of a significant difference in the ROC curve analyses. Compared with the RNA-SNP approach, the diagnostic sensitivities and specificities of the total PLAC4 mRNA-quantification approach were lower (Table 2) , possibly because of the relatively large interindividual variation in the concentration of PLAC4 mRNA in maternal plasma. The diagnostic accuracy could be improved by developing a placenta-specific reference mRNA transcribed from an unaffected chromosome to control for the variation in maternal plasma (25 ) . The results obtained in this study have expanded on our previous observation that the median plasma concentration of PLAC4 mRNA tends to be increased in trisomy 21 pregnancies, compared with euploid pregnancies (11 ) , although the results did not reach statistical significance in our earlier study. In the present study, we detected a statistically significant difference between euploid and trisomy 21 pregnancies in the plasma concentration of PLAC4 mRNA. One possible reason for this result is our use of a sample size larger than that used in the previous study (11 ) . Another reason might be the use of different realtime quantitative PCR assays: The current assay targets a PLAC4 mRNA amplicon 398 bases upstream of that of the previous assay (11 ) . Because the copy number of mRNA fragments decreases in a 5Ј-to-3Ј manner (26 ), we expect more target mRNA fragments to be available for the current assay and thus expect a lower imprecision than the previous assay (11 ) . Such an improvement would be expected to allow one to see a quantitative difference between the trisomy 21 and euploid groups more readily.
Our results indicate that the diagnostic value of circulating PLAC4 mRNA could be maximized by using the strategy outlined in Fig. 1 . One way of adopting the strategy in practice is that the PLAC4 mRNAquantification step also determines whether a sample should proceed to the "conventional (i.e., nondigital) strategy" or the "digital strategy." The digital strategy, although more costly, is especially useful for analyzing plasma samples with low PLAC4 mRNA concentrations, such as those collected from pregnant women very early in gestation. The digital strategy has an overall diagnostic accuracy similar to that of the conventional strategy. The digital method has the advantages of enhanced analytical sensitivity and precision in detecting circulating nucleic acids in maternal plasma (27 ) . Regardless of which arm of the strategy a sample follows, pregnant women with heterozygous fetuses could be assessed with the more accurate RNA-SNP approach, whereas pregnant women with homozygous fetuses could be risk-assessed by referring back to the PLAC4 mRNA-quantification approach. When we combine the data from the RNA-SNP approach and the PLAC4 mRNA-quantification approach for the population as a whole, we achieve diagnostic specificities of 80% and 69% for the conventional (nondigital) and the digital strategies, respectively, at a fixed diagnostic sensitivity of 100%.
The importance of the current work is that this strategy of combining the total concentration of placental mRNA and the RNA-SNP allelic ratio can essentially be applied to all pregnant women. The coverage of the more accurate RNA-SNP arm of the testing strategy would potentially be increased by the use of additional SNPs and other placental-mRNA markers. The development of additional markers is especially important for populations that have a low heterozygosity for the studied PLAC4 SNP. This approach is also potentially useful for detecting other chromosomal aneuploidies, e.g., trisomy 18 (28 ) and trisomy 13, if methods could be developed for assessing circulating placental mRNAs from the involved chromosomes.
